data:image/jpeg;base64,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Omega 3 e aspirina sono un’accoppiata vincente contro l’infiammazione: se i primi sono il materiale di partenza utilizzato dall’organismo per molecole in grado letteralmente di “spegnere” i processi infiammatori, la seconda aiuta le cellule a dare il via alla produzione di queste sostanze dall’attività antinfiammatoria. A svelare questo meccanismo è uno studio pubblicato sulla rivista Chemistry & Biology dai ricercatori dell’Harvard Medical School di Boston e dell’University of Southern California di Los Angeles (Stati Uniti).
Le sostanze in questione sono le resolvine, note per la loro capacità di contrastare l’infiammazione associata a disturbi come le malattie polmonari infiammatorie, quelle cardiache e l’artrite.
E’ noto che l‘aspirina è in grado di inibire in modo irreversibile un enzima infiammatorio, la ciclossigenasi, per interrompere la sintesi di molecole, le prostacicline e le prostaglandine, che propagano l’infiammazione; ciò che gli autori dello studio hanno evidenziato è che l’aspirina è anche in grado di produrre, dagli acidi grassi omega 3, alcune molecole, come la resolvina D3, che aiutano a far terminare l’infiammazione.
Non solo, hanno anche scoperto che, rispetto ad altre resolvine, la D3 rimane più a lungo nei siti dell’infiammazione, dove potrebbe svolgere delle funzioni specifiche nelle fasi finali della battaglia contro i processi infiammatori dannosi per l’organismo.
Somministrate a cellule umane o a topi, la forma di resolvina D3 prodotta in presenza di aspirina esercita una potente azione antinfiammatoria.
Infine, i ricercatori hanno identificato i recettori che nelle cellule umane vengono attivati dalla resolvina D3. Con queste informazioni alla mano sarà possibile approfondire ulteriormente la conoscenza dei meccanismi antinfiammatori in cui è coinvolta questa molecola e capire quali malattie infiammatorie potrebbero essere trattate sfruttando la sua attività

Commenti chiusi